ArticleCancer treatment and research communications2026

KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.

Ziheng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.